HOME ABOUT US SCIENCE PIPELINE COLLABORATIONS INVESTORS CONTACT The suprachoroidal space Drugs precisely delivered by suprachoroidal injection with access to the choroid and the retina where the diseases present. WATCH ANIMATION The suprachoroidal space provides a novel treatment approach Targeted The back of the eye is the location of many irreversible and debilitating visual impairments2 Bioavailable Fluid spreads circumferentially and posteriorly when injected within the suprachoroidal space, bathing the choroid and adjacent areas with drug1 Compartmentalized Drug is compartmentalized in the suprachoroidal space, which helps keep it away from nondiseased tissues1 HOMEABOUT USSCIENCEPIPELINECOLLABORATIONSINVESTORSCAREERSCONTACTPRIVACY Powered by Innovasium

Skip to main navigation HOME ABOUT US SCIENCE PIPELINE COLLABORATIONS INVESTORS CONTACT Investor Relations IR Overview News Events and Presentations Governance SEC Filings Financial Info Resources Management Team George Lasezkay, Pharm.D., J.D. President and Chief Executive Officer Thomas A. Ciulla, M.D., MBA Chief Medical Officer and Chief Development Officer Charles A. Deignan Chief Financial Officer Rafael V. Andino Vice President, Engineering & Manufacturing Rick McElheny Vice President, Business Development Leslie Zacks General Counsel & Chief Compliance Officer Vice Presidents Barbara H. Bauschka Vice President, Regulatory Thomas Crawford Vice President, Supply Chain Colette Hall, MD Vice President, Safety Viral Kansara, Ph.D. Vice President, Discovery Lester Rodriguez Vice President, Quality Board of Directors William D. Humphries Chairman of the Board Richard Croarkin Jeffrey L. Edwards Nancy J. Hutson, Ph.D. George Lasezkay, Pharm.D., J.D. President and Chief Executive Officer Christy Shaffer, Ph.D. Venture Partner and Managing Director of Hatteras Discovery Clay B. Thorp General Partner with Hatteras Venture Partners Footer HOME ABOUT US SCIENCE PIPELINE COLLABORATIONS INVESTORS CAREERS CONTACT PRIVACY